Invasive fungal diseases are a leading cause of mortality among immune-compromised populations. Treatment is notoriously difficult due to the limited number of antifungal drugs as well as the emergence of drug resistance. Tamoxifen (TAM), a selective estrogen receptor modulator frequently used for treatment of breast cancer, has been found to have antifungal activities, and may be a useful addition to treat fungal infectious diseases. However, its molecular mechanisms underlying the antifungal actions remain obscure. Here, we screened for mutations that conferred sensitivity to antifungal drug azoles by using fission yeast as a model, and isolated the cls1 (ccr1) mutant, an allele of the gene encoding NADPH-cytochrome P450 reductase Ccr1. We found that deletion of ccr1+ gene exhibited hypersensitivities to various drugs, including antifungal drugs azoles, terbinafine, micafungin, immunosuppressor FK506, anticancer drugs TAM and 5-fluorouracil (5-FU). Unexpectedly, overexpression of Ccr1 caused yeast cells resistance to TAM, but not the other drugs tested here. Additionally, deletion of Ccr1 displayed pleiotropic phenotypes, including defects in cell wall integrity and vacuole fusion, enhanced calcineurin activity as well as increased intracellular Ca2+ levels. Overexpression of the constitutively active calcineurin suppressed the drug sensitive phenotypes of the Δccr1 cells. Notably, TAM treatment on wild-type cells resulted in pleiotropic phenotypes, similar to that of Ccr1 lacking. Furthermore, TAM inhibited NADPH-cytochrome P450 reductase activities Ccr1 activity in a dose-dependent manner. Moreover, TAM treatment also inhibited NADPH-cytochrome P450 reductase activities of Candida albicans and resulted in defective cell wall integrity. Collectively, our findings suggest that Ccr1 is a novel target of TAM and is involved in the antifungal activity of TAM through regulating cell wall integrity in fission yeast.
Enhancer of zeste homologue 2 (EZH2), a catalytic subunit of polycomb repressive complex 2, is overexpressed in a number of different tumors including breast cancer, and serves important roles in cell cycle regulation, proliferation, apoptosis, tumorigenesis and drug resistance. However, it remains unclear whether EZH2 contributes to tamoxifen resistance in breast cancer. In the present study, the role of EZH2 in tamoxifen resistance in MCF‑7 cells was investigated. EZH2 was overexpressed in MCF‑7 tamoxifen‑resistant (MCF‑7 TamR) cells. EZH2 overexpression decreased the sensitivity of MCF‑7 cells to tamoxifen, and EZH2 knockdown improved the sensitivity of MCF‑7 TamR cells to tamoxifen. Furthermore, EZH2 knockdown induced cell cycle arrest in MCF‑7 TamR cells, accompanied by a decrease in cyclin D1 expression and an increase in p16 expression. EZH2 knockdown reduced p16 gene methylation in MCF‑7 TamR cells. These findings suggested that EZH2 overexpression may contribute to tamoxifen resistance in breast cancer, and EZH2 inhibition may reverse tamoxifen resistance in breast cancer by regulating the cell cycle via the demethylation of the p16 gene. Thus, EZH2 inhibitors may be effective for treating tamoxifen resistance in breast cancer.
1 November 2018 in Antimicrobial Agents and Chemotherapy
The fight against resistance to antifungal drugs requires a better understanding of the underlying cellular mechanisms. To gain insight into the mechanisms leading to antifungal drug resistance, we performed a genetic screen to identify genes whose overexpression caused resistance to the antifungal drugs including clotrimazole and terbinafine using a model organism, Schizosaccharomyces pombe (S. pombe), and identified the phb2+ gene encoding a highly conserved mitochondrial protein prohibitin Phb2, as a novel determinant of multidrug resistance. Unexpectedly, deletion of the phb2+ gene also exhibited antifungal drug resistance. Overexpression of the phb2+ gene failed to cause the drug resistance when the pap1+ gene encoding an oxidative stress responsive transcription factor was deleted. Furthermore, pap1+ mRNA expression was significantly increased when the phb2+ gene was overexpressed or deleted. Importantly, either overexpression of phb2+ or deletion of its gene stimulated NO and ROS synthesis as measured by a cell-permeant fluorescent NO probe DAF-FM DA and a ROS probe DCFH-DA, respectively. Altogether, these results suggest that dysfunction of Phb2 results in multidrug resistance via increasing NO and ROS synthesis due to dysfunctional mitochondria, thereby activating transcription factor Pap1 in fission yeast.
Hydrogen peroxide (H2O2) induces oxidative stress and cytotoxicity, and can be used for treating cancers in combination with radiotherapy. A product comprising H2O2 and sodium hyaluronate has been developed as a radiosensitizer. However, the effects of H2O2 on antitumor immunity remain unclear. To investigate the effects of H2O2, especially the abscopal effect when combined with radiotherapy (RT), we implanted murine tumor cells simultaneously in two locations in mouse models: the hind limb and back. H2O2 mixed with sodium hyaluronate was injected intratumorally, followed by irradiation only at the hind limb lesion. No treatment was administered to the back lesion. The H2O2/RT combination significantly reduced tumor growth at the noninjected/nonirradiated site in the back lesion, whereas H2O2 or RT individually did not reduce tumor growth. Flow cytometric analyses of the tumor-draining lymph nodes in the injected/irradiated areas showed that the number of dendritic cells increased significantly with maturation in the H2O2/RT combination group. In addition, analyses of tumor-infiltrating lymphocytes showed that the number of CD8(+) (cluster of differentiation 8) T cells and the frequency of IFN-?(+) (interferon gamma) CD8(+) T cells were higher in the noninjected/nonirradiated tumors in the H2O2/RT group compared to those in the other groups. PD-1 (programmed death receptor 1) blockade further increased the antitumor effect against noninjected/nonirradiated tumors in the H2O2/RT group. Intratumoral injection of H2O2 combined with RT therefore induces an abscopal effect by activating antitumor immunity, which can be further enhanced by PD-1 blockade. These findings promote the development of H2O2/RT therapy combined with cancer immunotherapies, even for advanced cancers.